{
	"symbol": "CSCI",
	"name": "COSCIENS Biopharma Inc.",
	"price": 4.12,
	"priceChange": 0.06,
	"percentChange": 1.477833,
	"exchangeName": "Toronto Stock Exchange",
	"exShortName": "TSX",
	"exchangeCode": "TSX",
	"marketPlace": null,
	"sector": "Healthcare",
	"industry": "Biotechnology",
	"volume": 1530,
	"openPrice": 4.23,
	"dayHigh": 4.23,
	"dayLow": 4.06,
	"MarketCap": 15486491,
	"MarketCapAllClasses": 7387198,
	"peRatio": "",
	"prevClose": 4.06,
	"dividendFrequency": null,
	"dividendYield": null,
	"dividendAmount": null,
	"dividendCurrency": null,
	"beta": 2.262891,
	"eps": null,
	"exDividendDate": "",
	"longDescription": "AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland, Ireland, Denmark, and others, of which nearly all of its revenue comes from Switzerland.",
	"fulldescription": "AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland, Ireland, Denmark, and others, of which nearly all of its revenue comes from Switzerland.",
	"website": "https://www.zentaris.com",
	"email": "IR@aezsinc.com",
	"phoneNumber": "+1 843 900-3223",
	"fullAddress": "c/o Norton Rose Fulbright Canada, LLP,222 Bay Street, Suite 3000, PO Box 53, Toronto, ON, CA",
	"employees": "21",
	"shareOutStanding": 3758857,
	"totalDebtToEquity": 0.06,
	"totalSharesOutStanding": 1793009,
	"sharesESCROW": null,
	"vwap": 4.10466666,
	"dividendPayDate": null,
	"weeks52high": 15.13,
	"weeks52low": 3.78,
	"alpha": -0.042026,
	"averageVolume10D": 3804,
	"averageVolume20D": 2464,
	"averageVolume30D": 2090,
	"averageVolume50D": 1762,
	"priceToBook": 0.21,
	"priceToCashFlow": -1,
	"returnOnEquity": -61.31,
	"returnOnAssets": -35.13,
	"day21MovingAvg": 4.649048,
	"day50MovingAvg": 4.9696,
	"day200MovingAvg": 8.2468,
	"dividend3Years": "",
	"dividend5Years": "",
	"datatype": "equity",
	"issueType": "CS",
	"close": 4.12,
	"qmdescription": "Biotechnology",
	"__typename": "Company"
}